Concepedia

Publication | Closed Access

Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.

24

Citations

0

References

2007

Year

Britta A. P. Laros‐van Gorkom, C A M Huisman, P. W. Wijermans, Martin R. Schipperus
PubMed

Abstract

Treatment with alemtuzumab is often terminated prematurely, leading to a suboptimal treatment effect. Fear of severe uncontrollable opportunistic infections seems unjustified.